Zymeworks reported that its folate‑receptor‑α‑targeting antibody‑drug conjugate ZW191 achieved a confirmed objective response rate of 56% across all dose levels in a dose‑escalation Phase 1 study. In platinum‑resistant ovarian cancer patients receiving 6.4‑9.6 mg/kg, the response rate rose to 61%, and disease control was achieved in 94% of patients. The median duration of response had not been reached at the data cutoff, indicating durable activity.
The safety profile was manageable. Grade ≥ 3 treatment‑emergent adverse events occurred in 55% of patients, with neutropenia (24%), anemia (20%) and thrombocytopenia (12%) being the most common. Serious adverse events were observed in 35% of patients, and 20% discontinued treatment because of adverse events. No new safety signals were identified, and the maximum tolerated dose was not reached up to 11.2 mg/kg.
"We are highly encouraged by the initial clinical data for ZW191, which reinforce the strength of our ADC platform and its ability to generate differentiated therapeutics," said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer. "The breadth and durability of responses, along with activity across varying levels of FRα expression, support further development of ZW191 as a potential best‑in‑class agent for patients with ovarian and endometrial cancers," she added. Lead author Patricia LoRusso, DO, PhD, noted, "These data demonstrate the potential of ZW191 to deliver meaningful clinical benefit in patients with heavily pre‑treated gynecological tumors with limited options. The combination of encouraging response rates and manageable safety profile supports further development of this therapy, particularly in ovarian and endometrial cancers where new treatment options are urgently needed."
The results reinforce Zymeworks’ strategy of advancing differentiated ADCs and provide a strong foundation for future development of ZW191 in ovarian and endometrial cancers. The activity across varying FRα expression levels suggests a broader patient population could benefit, and the manageable safety profile positions the asset favorably for regulatory and partnership discussions. These data strengthen the company’s platform capabilities and may accelerate the path to clinical development and potential commercialization.
The Phase 1 data underscore the promise of ZW191 and validate the company’s ADC platform, offering a compelling basis for continued investment in the candidate’s development program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.